Sol-Gel Technologies Ltd. (SLGL)
| Market Cap | 240.13M |
| Revenue (ttm) | 22.90M |
| Net Income (ttm) | -24.61M |
| Shares Out | 19.53M |
| EPS (ttm) | -1.34 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 20 |
| Last Price | $10.29 |
| Previous Close | $10.44 |
| Change ($) | -0.15 |
| Change (%) | -1.44% |
| Day's Open | 10.51 |
| Day's Range | 10.26 - 10.77 |
| Day's Volume | 10,677 |
| 52-Week Range | 5.88 - 14.00 |
NESS ZIONA, Israel, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializ...
- PDUFA Goal Date Set for August 1, 2021
Sol-Gel Technologies (SLGL) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Patented technology for slow release of topical formulations. Potentially the first single-active benzoyl peroxide to be approved as a prescription drug.
Shares of Sol-Gel Technologies (NASDAQ:SLGL) moved higher by 0.1% after the company reported Q3 results. Quarterly Results Earnings per share increased 0.00% year over year to ($0.37), which b...
NESS ZIONA, Israel, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing bra...
NESS ZIONA, Israel, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializ...
- PDUFA Goal Date Set for April 26, 2021
NESS ZIONA, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercia...
NESS ZIONA, Israel, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing ...
NESS ZIONA, Israel, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing b...
NESS ZIONA, Israel, July 29, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, dev...
NESS ZIONA, Israel, July 28, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing b...
Generic Product Collaborations between the Companies Now Cover Ten Products Generic Product Collaborations between the Companies Now Cover Ten Products
NESS ZIONA, Israel, June 16, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, dev...
NESS ZIONA, Israel, May 14, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing br...
Investment is for ordinary shares and warrants to purchase ordinary shares at a combined price of $11 per ordinary share and accompanying warrants to purchase 0.80 of an ordinary share
NESS ZIONA, Israel, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, dev...
Successful topline results, strengthens Epsolay’s long-term safety and tolerability profile in the treatment of papulopustular rosacea
Sol-Gel Technologies: A Promising Small-Cap Dermatology Player In 2020
NESS ZIONA, Israel, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”) a clinical-stage dermatology company focused on identifying, deve...
The under-the-radar pharma company might have one of the industry's more promising approaches to dermatology treatments.
Sol-Gel Shines In Treating 2 Skin Disorders, NDAs Expected For Both Indications In 2020
NESS ZIONA, Israel, Jan. 02, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) today announced the initiation of a Phase 1 proof of concept clinical study of SGT-210, its no...
The small-cap company announced promising results from a clinical trial.
Sol Gel Technologies (SLGL) news for Monday concerning an acne drug study with incredibly positive results has SLGL stock taking off. The post Sol Gel Technologies News: SLGL Stock Skyrockets ...
Shares of the Israel-based, clinical-stage dermatology company Sol Gel Technologies Ltd (NASDAQ: SLGL) were more than doubling Monday.
Shares of Sol-Gel Technologies Ltd. SLGL, -5.82% gained 154% in premarket trading on Monday after the Israeli drugmaker said its acne drug Twyneo met the primary endpoints in two late-stage tr...
NESS ZIONA, Israel, Dec. 30, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) today announced top-line results from two pivotal Phase 3 clinical trials for Twyneo®, an inv...
NESS ZIONA, Israel, Oct. 16, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) today announced it will present research on the use of its proprietary microencapsulation tech...
Sol-Gel Technologies Ltd. (SLGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Sol-Gel Technologies Ltd. said Monday that two late-stage trials of a treatment for papulopustular rosacea produced positive results.
Sol-Gel Technologies Ltd. (SLGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
About SLGL
Sol-Gel Technologies, a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, which has completed Phase II clinical trials for the treatment of acne vulgaris; Epsolay that has completed Phase II clinical trials for the treatment of papulopustular rosacea; SGT-210, a epidermal growth factor receptor inhibitor, which is in development for the treatmen... [Read more...]
| Industry Biotechnology | IPO Date Jan 23, 2018 |
| CEO Alon Seri-Levy | Employees 61 |
| Stock Exchange NASDAQ | Ticker Symbol SLGL |
Financial Performance
In 2019, SLGL's revenue was $22.90 million, an increase of 17,655.04% compared to the previous year's $129,000. Losses were -$24.61 million, -23.58% less than in 2018.
Analyst Forecasts
According to 4 analysts, the average rating for SLGL stock is "Buy." The 12-month stock price forecast is 20.00, which is an increase of 94.36% from the latest price.